Clearside Biomedical (CLSD) News Today $1.01 -0.01 (-0.98%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Analysts Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $5.17November 2 at 4:09 AM | americanbankingnews.comClearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024October 31 at 7:05 AM | globenewswire.comClearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of "Buy" by AnalystsClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) has been given a consensus rating of "Buy" by the six analysts that are presently covering the company, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have covereOctober 28, 2024 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Sees Significant Growth in Short InterestClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 1,950,000 shares, an increase of 646.6% from the September 30th total of 261,200 shares. Based on an average daily volume of 718,700 shares, the days-to-cover ratio is presently 2.7 days.October 25, 2024 | marketbeat.comClearside Biomedical announces multiple presentations delivered at 2024 AAOOctober 22, 2024 | markets.businessinsider.comClearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual MeetingOctober 22, 2024 | globenewswire.comClearside Biomedical (NASDAQ:CLSD) Rating Increased to Hold at StockNews.comStockNews.com raised shares of Clearside Biomedical from a "sell" rating to a "hold" rating in a report on Friday.October 18, 2024 | marketbeat.comChardan Capital Reaffirms "Buy" Rating for Clearside Biomedical (NASDAQ:CLSD)Chardan Capital reaffirmed a "buy" rating and set a $6.00 target price on shares of Clearside Biomedical in a report on Monday.October 14, 2024 | marketbeat.comMorning Movers: Arcadium Lithium surges after deal to be acquiredOctober 11, 2024 | finance.yahoo.comClearside Biomedical’s CLS-AX Shows Promising Phase 2b Results for Wet AMD, Justifying a Buy Rating with a $6.00 TargetOctober 10, 2024 | markets.businessinsider.comBuy Rating Affirmed with Increased Price Target for Clearside Biomedical Post-ODYSSEY Trial SuccessOctober 10, 2024 | markets.businessinsider.comBuy Rating on Clearside Biomedical: Promising ODYSSEY Trial Results and Undervalued Market PositionOctober 9, 2024 | markets.businessinsider.comClearside stock falls 12% amid Phase 2 data for CLS-AXOctober 9, 2024 | msn.comClearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage StudyOctober 9, 2024 | finance.yahoo.comClearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary OutcomesOctober 9, 2024 | globenewswire.comClearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of "Buy" by AnalystsClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) has been given a consensus recommendation of "Buy" by the six brokerages that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 1 year target price among brokers that haveOctober 3, 2024 | marketbeat.comArmistice Capital LLC Decreases Position in Clearside Biomedical, Inc. (NASDAQ:CLSD)Armistice Capital LLC lessened its stake in Clearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) by 46.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,136,000 shares of the company's stock after selling 1,820,000 sharSeptember 27, 2024 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Sees Large Increase in Short InterestClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 335,200 shares, an increase of 86.0% from the August 15th total of 180,200 shares. Based on an average daily trading volume, of 220,800 shares, the days-to-cover ratio is currently 1.5 days.September 13, 2024 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Rating of "Buy" from BrokeragesClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) has been assigned a consensus rating of "Buy" from the six brokerages that are covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average twelve-month target price among brokeragSeptember 8, 2024 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Shares Pass Below 50 Day Moving Average of $1.12Clearside Biomedical (NASDAQ:CLSD) Shares Pass Below 50 Day Moving Average of $1.12September 6, 2024 | marketbeat.comBuy Rating for Clearside Biomedical’s CLS-AX Based on Superior Efficacy and Market Adoption PotentialSeptember 3, 2024 | markets.businessinsider.comClearside Biomedical: A Strong Buy on Promising ODYSSEY Trial Outcomes and Market Re-Rating PotentialAugust 27, 2024 | markets.businessinsider.comOptimistic Buy Rating for Clearside Biomedical Amid Promising ODYSSEY Trial Results and Strong Financial PositionAugust 27, 2024 | markets.businessinsider.comClearside Biomedical's (CLSD) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Clearside Biomedical in a research note on Tuesday.August 27, 2024 | marketbeat.comClearside Biomedical, Inc.: Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMDAugust 27, 2024 | finanznachrichten.deClearside Slips on TrialsAugust 27, 2024 | msn.comClearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMDAugust 27, 2024 | globenewswire.comBrokers Issue Forecasts for Clearside Biomedical, Inc.'s FY2024 Earnings (NASDAQ:CLSD)Clearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) - Chardan Capital issued their FY2024 EPS estimates for shares of Clearside Biomedical in a report released on Wednesday, August 21st. Chardan Capital analyst D. Gataulin forecasts that the company will earn ($0.55) per share for the year. ChAugust 26, 2024 | marketbeat.comAssenagon Asset Management S.A. Buys Shares of 283,193 Clearside Biomedical, Inc. (NASDAQ:CLSD)Assenagon Asset Management S.A. purchased a new position in Clearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 283,193 shares of the company's stock, valued at apprAugust 25, 2024 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Research Coverage Started at Chardan CapitalChardan Capital assumed coverage on shares of Clearside Biomedical in a research note on Wednesday. They issued a "buy" rating and a $6.00 target price on the stock.August 21, 2024 | marketbeat.comCLSD Sep 2024 2.500 callAugust 17, 2024 | ca.finance.yahoo.comClearside Biomedical, Inc. (NASDAQ:CLSD) to Post Q3 2024 Earnings of ($0.13) Per Share, HC Wainwright ForecastsClearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) - Stock analysts at HC Wainwright raised their Q3 2024 EPS estimates for Clearside Biomedical in a research report issued to clients and investors on Tuesday, August 13th. HC Wainwright analyst Y. Chen now expects that the company will post eAugust 15, 2024 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Up 76.8% in JulyClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) saw a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 206,900 shares, a growth of 76.8% from the July 15th total of 117,000 shares. Based on an average trading volume of 184,400 shares, the days-to-cover ratio is currently 1.1 days.August 14, 2024 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of "Buy" by BrokeragesShares of Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) have received a consensus rating of "Buy" from the five brokerages that are covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 12 month target price aAugust 14, 2024 | marketbeat.comBuy Rating for Clearside Biomedical Amid Strong Clinical Progress and Positive Financial OutlookAugust 13, 2024 | markets.businessinsider.comClearside Biomedical (NASDAQ:CLSD) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and set a $5.00 price target on shares of Clearside Biomedical in a research note on Tuesday.August 13, 2024 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Posts Earnings Results, Beats Estimates By $0.04 EPSClearside Biomedical (NASDAQ:CLSD - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.04. The company had revenue of $0.09 million for the quarter, compared to analysts' expectations of $0.25 million. During the same period in the previous year, the business earned ($0.15) earnings per share.August 13, 2024 | marketbeat.comClearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | finance.yahoo.comBuy Rating Affirmed for Clearside Biomedical Ahead of ODYSSEY Trial ResultsAugust 13, 2024 | markets.businessinsider.comCLSD Stock Earnings: Clearside Biomedical Beats EPS, Misses Revenue for Q2 2024August 12, 2024 | investorplace.comClearside Biomedical Q2 2024 Earnings PreviewAugust 12, 2024 | msn.comClearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceAugust 8, 2024 | globenewswire.comClearside Biomedical (CLSD) Set to Announce Quarterly Earnings on MondayClearside Biomedical (NASDAQ:CLSD) will be releasing earnings after the market closes on Monday, August 12, Zacks reports.August 5, 2024 | marketbeat.comClearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024August 1, 2024 | globenewswire.comBuy Rating Affirmed for Clearside Biomedical on Promising Phase 3 Results and Innovative Drug Delivery SystemJuly 31, 2024 | markets.businessinsider.comClearside Biomedical's (CLSD) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $5.00 target price on shares of Clearside Biomedical in a research report on Tuesday.July 30, 2024 | marketbeat.comBuy Rating Affirmed for Clearside Biomedical on Successful Drug Delivery Innovations and Positive Clinical ResultsJuly 30, 2024 | markets.businessinsider.comClearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest UpdateClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) was the target of a large decline in short interest in July. As of July 15th, there was short interest totalling 117,000 shares, a decline of 48.4% from the June 30th total of 226,900 shares. Based on an average daily trading volume, of 174,200 shares, the days-to-cover ratio is currently 0.7 days.July 26, 2024 | marketbeat.comClearside Biomedical, Inc. (CLSD) Suprachoroidal Space Drug Delivery (Transcript)July 25, 2024 | seekingalpha.comClearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ETJuly 22, 2024 | globenewswire.com Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025. Click here to see the surprising reason why CLSD Media Mentions By Week CLSD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLSD News Sentiment▼0.490.42▲Average Medical News Sentiment CLSD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLSD Articles This Week▼32▲CLSD Articles Average Week Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Marker Therapeutics News Today Eyenovia News Today iTeos Therapeutics News Today uniQure News Today Fate Therapeutics News Today Design Therapeutics News Today AC Immune News Today Sutro Biopharma News Today Inozyme Pharma News Today UroGen Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLSD) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
